CENTER ON BEHAVIORAL MEDICINE

BODY-MIND CONNECTION

ESSENTIAL NUTRIENTS

Essential Nutrients-Behavior:  Research Article

Essential Nutrients Menu

Zinc Sulfate as Treatment of Attention Deficit Hyperactivity Disorder in Children

CITATION:  Akhondzadeh, S., Mohammadi-Rexa, S., and Khademi M.  (2004)  Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit Hyperactivity disorder in children: A double blind and randomized trial.  BMC Psychiatry 2004, 4:9.

ABSTRACT:  

Background. Attention-deficit hyperactivity disorder is an early-onset, clinically heterogenous disorder of inattention, hyperactivity, and impulsiveness. The diagnosis and treatment of attention-deficit  hyperactivity disorder continues to raise controversy, and, there is also an increase in treatment options.  In this 6-week double blind, placebo controlled-trial, we assessed the effects of zinc plus methylphenidate in the treatment of children with attention deficit hyperactivity disorder. To the best of our knowledge,  this study is the first double blind and placebo controlled clinical trial assessing the adjunctive role of zinc
in ADHD.

Methods. Our subjects were 44 outpatient children (26 boys and 18 girls) between the ages of 5–11 (mean SD was 7.88 1.67) who clearly met the DSM IV diagnostic criteria for attention-deficit hyperactivity disorder and they were randomized to methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/ day (with approximately 15 mg zinc element) (group 1) and methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg) (group 2) for a 6 week double blind clinical trial. The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist at baseline, 14, 28 and 42 days after the medication started.

Results. The present study shows the Parent and Teacher Rating Scale scores improved with zinc sulfate over this 6-week, double blind and placebo controlled trial. The behavior of the two treatments was not  homogeneous across the time. The difference between the two protocols was significant as indicated by
the effect on the group, the between-subjects factor (F = 4.15, d.f. = 1, P = 0.04; F = 4.50, d.f. = 1, P = 0.04 respectively). The difference between the two groups in the frequency of side effects was not significant.

Conclusions. This double-blind, placebo-controlled study demonstrated that zinc as a supplementary medication might be beneficial in the treatment of children with attention-deficit hyperactivity disorder. However, further investigations and different doses of zinc are required to replicate these findings in children with ADHD.

References

1. Goldman L, Genel M, Bezman R, Slanetz P: Diagnosis and treatment
of attention deficit/hyperactivity disorder in children
and adolescents. JAMA 1998, 279:1100-1107.

2. Mercuglioano M: What is attention-deficit/hyperactivity
disorder? Pediatr Clin North Am 1999, 46:831-43.

3. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders, (DSM-IV). American Psychiatric Association,
Washington, D.C 41994.

4. Wilens TE, Biederman J: The stimulants. Psychiatr Clin North Am
1992, 15:191-222.

5. Gillberg C, Melander H, Knorring A: Long-term stimulant treatment
of children with attention-deficit hyperactivity disorder
symptoms. Arch Gen Psychiat 1997, 54:857-864.

6. Safer DJ: Central stimulant treatment of childhood attention
deficit hyperactivity disorder. CNS Drugs 1997, 7:264-272.

7. Tenreiro K: Methylphenidate-placebo: A trial for attention
deficit disorders. Int J Pharm Comp 2001, 5:21-22.

8. Klein RG, Landa B: Methylphenidate and growth in hyperactive
children. Arch Gen Psychiat 1988, 45:1127-1130.

9. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Blancanlello TM: Side
effects of methylphenidate and desipramine alone and in
combination in children. J Am Acad Child Adolesc Psychiatry 1993,
32:1065-1072.

10. Prince JB, Wilens TE, Biederman J: A controlled study of
nortriptyline in children and adolescents with attention deficit
hyperactivity disorder. J Child & Adolesc Psychopharmacol 2000,
10:193-204.

11. Kehpe WA: Treatment of attention deficit hyperactivity disorder
in children. The Ann Pharmacother 2001, 35:1130-1134.

12. Toren P, Elder S, Sela BA, Wolmer L, Weitz W, Inbar D, Koren S,
Reiss A, Weizman R, Laor N: Zinc deficiency in attention deficit
hyperactivity disorder. Biol Psychiat 1996, 40:1308-1310.

13. Bekarglu M, Aslan Y, Gedik Y, Deger O, Mocan H, Erduran E, Karahan
C: Relation between serum free fatty acids and zinc, and
attention deficit hyperactivity disorder: A research note. J
Child Psyhol Psychiat 1996, 37:225-227.

14. Kirby K, Floriani V, Bernstein H: Diagnosis and management of
attention-deficit hyperactivity disorder in children. Cur Opinion
in Pediatr 2001, 13:190-199.

15. World Medical Association Declaration of Helsinki: Ethical principles
for medical research involving human subjects. 2000
[http://www.wma.net].

16. Dupaul GP: Parent and teacher ratings of ADHD symptoms:
Psychometric properties in a community based sample. J Clin
Child Psychol 1991, 20:245-253.

17. Bilici M, Yildirim F, Kandil S, Berkaroglu M, Yildirmis S, Deger O,
Ulgen M, Yildiran A, Aksu H: Double blind, placebo-controlled
study of zinc sulfate in the treatment of attention deficit
hyperactivity disorder. Prog in Neuropsychopharm & Biol Psychiat
2004, 28:181-190.